Key result
Rivaroxaban prevents and treats thromboembolic events across multiple clinical indications.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bayer Pharmaceuticals (2017) studied Non-valvular atrial fibrillation, venous thromboembolism, deep vein thrombosis, pulmonary embolism. Rivaroxaban was evaluated. Rivaroxaban is a non-vitamin K oral anticoagulant indicated for the prevention and treatment of thromboembolic events across multiple indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: